



Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression[☆]



Rubén Gómez-Sánchez^a, Matthew E. Gegg^b, José M. Bravo-San Pedro^{a,c}, Mireia Niso-Santano^{a,c}, Lydia Alvarez-Erviti^b, Elisa Pizarro-Estrella^a, Yolanda Gutiérrez-Martín^d, Alberto Alvarez-Barrientos^d, José M. Fuentes^{a,*}, Rosa Ana González-Polo^{a,*}, Anthony H.V. Schapira^{b,1}

^a Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Departamento de Bioquímica y Biología Molecular y Genética, Universidad de Extremadura, F. Enfermería y Terapia Ocupacional, 10003 Cáceres, Spain

^b Department of Clinical Neurosciences, Institute of Neurology, University College London, London NW3 2PF, UK

^c INSERM, U848, Institut Gustave Roussy, Université Paris Sud, Paris 11, F-94805 Villejuif, France

^d Servicio de Técnicas Aplicadas a las Biotecnologías, Universidad de Extremadura, 06071 Badajoz, Spain

ARTICLE INFO

Article history:

Received 18 July 2013

Revised 6 October 2013

Accepted 22 October 2013

Available online 29 October 2013

Keywords:

SH-SY5Y

CCCP

Parkinson's disease

PINK1

Calcium

Mitophagy

ABSTRACT

Mutations of the *PTEN-induced kinase 1* (*PINK1*) gene are a cause of autosomal recessive Parkinson's disease (PD). This gene encodes a mitochondrial serine/threonine kinase, which is partly localized to mitochondria, and has been shown to play a role in protecting neuronal cells from oxidative stress and cell death, perhaps related to its role in mitochondrial dynamics and mitophagy. In this study, we report that increased mitochondrial PINK1 levels observed in human neuroblastoma SH-SY5Y cells after carbonyl cyanide m-chlorophenylhydrazone (CCCP) treatment were due to de novo protein synthesis, and not just increased stabilization of full length PINK1 (FL-PINK1). PINK1 mRNA levels were significantly increased by 4-fold after 24 h. FL-PINK1 protein levels at this time point were significantly higher than vehicle-treated, or cells treated with CCCP for 3 h, despite mitochondrial content being decreased by 29%. We have also shown that CCCP dissipated the mitochondrial membrane potential ($\Delta\psi_m$) and induced entry of extracellular calcium through L/N-type calcium channels. The calcium chelating agent BAPTA-AM impaired the CCCP-induced PINK1 mRNA and protein expression. Furthermore, CCCP treatment activated the transcription factor c-Fos in a calcium-dependent manner. These data indicate that PINK1 expression is significantly increased upon CCCP-induced mitophagy in a calcium-dependent manner. This increase in expression continues after peak Parkin mitochondrial translocation, suggesting a role for PINK1 in mitophagy that is downstream of ubiquitination of mitochondrial substrates. This sensitivity to intracellular calcium levels supports the hypothesis that PINK1 may also play a role in cellular calcium homeostasis and neuroprotection.

© 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized clinically by bradykinesia, rigidity or tremor, and pathologically by loss of nigrostriatal dopaminergic neurons and the presence of cytoplasmic protein inclusions known as Lewy bodies. The etiology of PD is still unknown, but genetic and possibly environmental

factors are thought to be involved (Duvoisin, 1999; Williams et al., 1999). Mitochondrial dysfunction has consistently been implicated in the pathogenesis of PD (Langston et al., 1983; Schapira et al., 1989), and different proteins associated with familial PD, such as PTEN-induced kinase 1 (PINK1), Parkin, DJ-1, LRRK2 and α -synuclein, have been reported to localize to mitochondria and affect function (Bonifati et al., 2003; Devi et al., 2008; Narendera et al., 2008; Papkovskaia et al., 2012; Silvestri et al., 2005; Valente et al., 2004).

Mutations in the *PINK1* gene are responsible for autosomal recessive familial PD (Valente et al., 2004). PINK1 is a 581 amino acid protein ubiquitously transcribed and encodes a serine/threonine kinase, showing high homology with the Ca^{2+} /calmodulin kinase family. Also, PINK1 contains a N-terminal mitochondrial targeting sequence and a C-terminal autoregulatory domain (Beilina et al., 2005; Silvestri et al., 2005; Sim et al., 2006) is predominantly localized to mitochondria, but also is present in the cytosol (Haque et al., 2008; Valente et al., 2004; Weihofen et al., 2008; Zhou et al., 2008). Full-length PINK1 (FL-PINK1), is approximately 63 kDa, and is transcribed in the nucleus, translated

[☆] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Corresponding authors at: Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Departamento de Bioquímica y Biología Molecular y Genética, Universidad de Extremadura, F. Enfermería y Terapia Ocupacional, 10003 Cáceres, Spain. Fax: + 34 927257451.

E-mail addresses: jfuentes@unex.es (J.M. Fuentes), rosapolo@unex.es (R.A. González-Polo).

Available online on ScienceDirect (www.sciencedirect.com).

¹ These authors contributed equally to this work.

in the cytoplasm and imported intact into mitochondria. PINK1 is then cleaved by the mitochondrial protease PARL (presenilin-associated rhomboid-like) at the inner mitochondrial membrane (Deas et al., 2011; Meissner et al., 2011; Whitworth et al., 2008) to yield two bands of 55 kDa (Δ N-PINK1) and 45 kDa (Δ N²-PINK1) (Lin and Kang, 2008; Muqit et al., 2006; Silvestri et al., 2005; Weihofen et al., 2008). The Δ N-PINK1 species is rapidly degraded by the proteasome (Takatori et al., 2008).

Previous reports using cell culture models suggest that PINK1 may play a neuroprotective role under several forms of stress conditions, because the over-expression of wild-type *PINK1*, but not mutant *PINK1*, protects against cell death induced by chemical stressors, such as the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or the proteasomal inhibitor carbobenzoxy-leucyl-leucyl-leucinal (MG-132) (Haque et al., 2008; Petit et al., 2005; Valente et al., 2004). Several studies in *Drosophila*, mouse and cell culture models, including fibroblasts from patients with *PINK1* mutations (Abramov et al., 2011; Grunewald et al., 2009; Hoepken et al., 2007; Piccoli et al., 2008), suggest that loss of *PINK1* can be associated with functional and morphological mitochondrial effects, oxidative stress and the balance between mitochondrial fission and fusion (Clark et al., 2006; Gautier et al., 2008; Gegg et al., 2009; Gispert et al., 2009; Heeman et al., 2011; Park et al., 2006; Poole et al., 2008; Sandebring et al., 2009; Yang et al., 2008). The mitochondrial dysfunction associated with *PINK1* deficiency has been linked to perturbed mitophagy, a cellular process by which old and damaged mitochondria are engulfed into double membrane vacuoles, called autophagosomes, that then fuse with lysosomes, resulting in autophagolysosomes, where mitochondria are subsequently degraded (Kim et al., 2007; Youle and Narendra, 2011). Loss of $\Delta\psi_m$ induced by mitochondrial uncouplers, like carbonyl cyanide m-chlorophenylhydrazone (CCCP), is an initial step in the removal of this organelle, initiating fission of the reticular mitochondrial network in the damaged mitochondria (Narendra et al., 2008; Twig et al., 2008). This event inhibits the processing of FL-PINK1 by PARL, leading to the accumulation of FL-PINK1 on the mitochondrial outer membrane (Jin et al., 2010; Matsuda et al., 2010; D.P. Narendra et al., 2010; Vives-Bauza et al., 2010). PINK1 then recruits Parkin to mitochondria via phosphorylation (Kondapalli et al., 2012; Matsuda et al., 2010), whereupon Parkin ubiquitinates mitochondrial proteins such as VDAC and the mitofusins (Gegg et al., 2010; Geisler et al., 2010; Ziviani et al., 2010). The ubiquitination of mitochondrial outer membrane proteins such as the mitofusins leads to their degradation by the proteasome, and is required for mitophagy (Chan et al., 2011; Tanaka et al., 2010).

Loss of PINK1 function results in decreased ATP synthesis by mitochondria, impaired mitochondrial calcium handling and increased oxidative stress in a time-dependent manner (Gautier et al., 2008; Gegg et al., 2009). The impairment of mitochondrial function is coincident with decreased macroautophagy flux (Gegg et al., 2010). Restoration of mitophagy in *PINK1*-deficient cells by exogenous expression of *parkin* results in improved mitochondrial function (Gegg et al., 2010), suggesting that impaired mitophagy may contribute to the mitochondrial dysfunction observed in PD.

Calcium plays a central role in regulating neurotransmitter release. Calcium influx is involved in the release of neurotransmitters by synaptic vesicles (Neher and Sakaba, 2008), synaptic plasticity (Zucker, 1999) and gene transcription (Lyons and West, 2011). Studies have implicated abnormal calcium homeostasis as a factor in the pathogenesis of PD, contributing to mitochondrial oxidative stress (Goldberg et al., 2012; Guzman et al., 2010) and dopaminergic neuronal death (Beal, 1998), or increasing levels of Ca²⁺-binding proteins calretinin and calbindin to confer some protection (Mouatt-Prigent et al., 1994; Yamada et al., 1990). Calcium regulation involves a range of different transcription factors, including c-Fos (FBJ murine osteosarcoma viral oncogene homolog) (Ng et al., 2012; Premkumar et al., 2000; Thompson et al., 1995; Zhang et al., 2002), CREB (cyclic AMP response element binding protein) (Soriano et al., 2006) and NF- κ B (nuclear factor- κ B) (Camandola et al., 2005; Furukawa and Mattson, 1998).

Furthermore, previous reports have shown that CCCP produces cytosolic [Ca²⁺] ([Ca²⁺]_c) elevations in different cell models (Babcock et al., 1997; Biswas et al., 1999; Eilam et al., 1990; Herrington et al., 1996; Komori et al., 2010; Lim et al., 2006; Pereira et al., 2008; Yan et al., 2012). This is consistent with the calcium entry from the outside (Ardon et al., 2009) and the inhibition of calcium uptake via the mitochondrial uniporter (mCU), pathway driven by the $\Delta\psi_m$.

Several studies indicate that PINK1 participates in mitochondrial calcium homeostasis (Gandhi et al., 2009; Heeman et al., 2011), possibly regulating the mitochondrial permeability transition pore (mPTP) (Akundi et al., 2011; Gautier et al., 2012), mitochondrial Na⁺/Ca²⁺ exchanger (NCXmito) (Gandhi et al., 2009) or mCU (Marongiu et al., 2009). Isoforms NCX2 and NCX3 may act downstream of PINK1, preventing mitochondrial calcium overload (Wood-Kaczmar et al., 2013).

In the current study, we show that the increase in FL-PINK1 levels seen upon CCCP treatment is not solely due to the stabilization of the protein on the mitochondrial outer membrane and decreased degradation by the proteasome (Jin et al., 2010; Matsuda et al., 2010; Narendra et al., 2008), but also to de novo PINK1 synthesis in a calcium-dependent pathway. Moreover, CCCP induced c-Fos activation through the extracellular calcium entrance by the L-type and N-type voltage-dependent calcium channels (VDCCs).

Material and methods

Cell culture

The human SH-SY5Y neuroblastoma cell line was cultured in 1:1 (v/v) DMEM:F12 (Ham) media containing 0.9 g/l glucose and supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, non-essential amino acids, and penicillin–streptomycin. The cells were seeded at a density of 2×10^6 in a 75-cm² tissue culture flask (Corning, New York, NY) and incubated at 37°C under saturating humidity in 5% CO₂/95% air.

Treatments

Cells were plated at a density of 1×10^6 cells/ml, and treated with CCCP (10 μ M, Sigma-Aldrich, St. Louis, MO) or an equivalent volume of ethanol (vehicle control, Sigma-Aldrich, St. Louis, MO) (Gegg et al., 2010). For the inhibition of transcription and translation, actinomycin D (Act. D) (5 μ g/ml, Fisher Scientific, Waltham, MA) and cycloheximide (CHX) (100 μ g/ml, Sigma-Aldrich, St. Louis, MO) were employed, respectively. The ubiquitin-proteasome system (UPS) and autophagy were inhibited with MG-132 (5 μ M, Tocris Bioscience, Bristol, UK), and bafilomycin A1 (Baf. A1) (100 nM, Sigma-Aldrich, St. Louis, MO), respectively. BAPTA-AM (5 μ M, Molecular Probes, Life Technologies, Carlsbad, CA) and EGTA (500 μ M, Sigma-Aldrich, St. Louis, MO) were used to chelate intracellular calcium and extracellular calcium, respectively. To inhibit the chaperone Hsp90, cells were incubated with 17-AAG (1 μ M, Calbiochem, Merck KGaA, Darmstadt, Germany). Cells were treated with all the inhibitors 1 h prior to CCCP, except 17-AAG, which was added 3 h before recovering the cells because of its toxicity. For the calcium live-cell imaging, we stimulated SH-SY5Y cells with these compounds just before the measurement: thapsigargin (1 μ M, Sigma-Aldrich, St. Louis, MO), rotenone (10 μ M, Sigma-Aldrich, St. Louis, MO) and Baf. A1 (100 nM) to deplete calcium stores (endoplasmic reticulum (ER), mitochondria and lysosomes, respectively); nifedipine (10 μ M, Sigma-Aldrich, St. Louis, MO) and ω -conotoxin GVIA (ω -CTX) (2 μ M, Alomone Labs, Jerusalem, Israel), L- and N-type VDCC blockers, respectively. In addition, cells were incubated with the following treatments for 24 h: calcium ionophore ionomycin (0.1–2 μ M, Sigma-Aldrich, St. Louis, MO) and L-type VDCC agonist Bay K 8644 (0.25–5 μ M, Tocris Bioscience, Bristol, UK).




Fig. 1. Mitochondrial damage and autophagy induction in SH-SY5Y CCCP-treated cells. (A) SH-SY5Y cells were exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control), lysed and CS activity measured. Data are expressed as nmol/min/mg protein (# $p > 0.05$; *** $p \leq 0.001$). (B and C) SH-SY5Y cells were treated with 10 μ M CCCP for 0, 3 or 24 h and lysates separated by SDS-PAGE and Western-blotting performed. Blots were probed with antibodies against two inner mitochondrial membrane proteins, COX IV and prohibitin 1. β -actin was used as a loading control. (B) Representative blot of at least three independent experiments. (C) Densitometry of each band expressed as % of control (# $p > 0.05$; * $p \leq 0.05$; ** $p \leq 0.01$). (D and E) SH-SY5Y cells were exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control) for 24 h, and stained with TMRM to assess $\Delta\psi_m$ by immunofluorescence. (D) Representative microphotographs of TMRM stain. Scale bar represents 10 μ m. The arrows highlight cells with low $\Delta\psi_m$. (E) TMRM fluorescence intensity per cell (in AU) by immunofluorescence (# $p > 0.05$; *** $p \leq 0.001$). (F and G) SH-SY5Y cells were exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control), harvested by trypsinization at different times and lysed. The ratio LC3-II/LC3-I was determined by Western-blotting. α -tubulin expression was used as a loading control. (F) Representative blot of at least three independent experiments. (G) Densitometry of each band expressed in arbitrary units of intensity (*** $p \leq 0.001$). Molecular mass is indicated in kilodaltons (kDa) next to the blots. Data were expressed as mean \pm SEM; $n = 3$. (H and I) SH-SY5Y cells were transfected with mCherry-GFP-LC3B plasmid for 24 h and treated with 10 μ M CCCP for 0, 3 or 24 h and fixed. (H) Representative immunofluorescence microphotographs. Autophagolysosomes and autophagosomes were labeled by red (mCherry-LC3B) and yellow puncta (mCherry-GFP-LC3B), respectively. The boxes highlight the pattern of each condition. (I) Percentages of mCherry (+) puncta per cell (# $p > 0.05$; *** $p \leq 0.001$). Scale bar represents 10 μ m.

Citrate synthase activity

Following treatments, cells were washed with PBS and lysed in 0.25% (v/v) Triton X-100 (Sigma-Aldrich, St. Louis, MO) in PBS supplemented with protease and phosphatase inhibitors. Debris was removed by centrifugation and citrate synthase (CS) activity was measured by following the oxidation of 5,5'-Dithiobis(2-nitrobenzoic acid) (Sigma-Aldrich, St. Louis, MO) in a spectrophotometer (absorbance at 412 nm) over time at 30°C in the presence of acetyl co-enzyme A (Sigma-Aldrich, St. Louis, MO) and oxaloacetate (Sigma-Aldrich, St. Louis, MO) (Clark and Land, 1974). Protein concentration was measured based on the bicinchoninic acid (BCA) method, using a Bicinchoninic Acid Kit (Sigma-Aldrich, St. Louis, MO) using bovine serum albumin (BSA) as a standard. The enzyme activity was expressed as nmol/min/mg protein.

Plasmid transfection

For the over-expression of PINK1 (to compare with the endogenous protein), SH-SY5Y cells were transfected with pCMV6-Neo vector containing full-length wild-type PINK1 cDNA (Origene), as previously described (Gegg et al., 2009), using FuGENE® 6 Transfection Reagent (Roche, Indianapolis, IN), according to the manufacturer's protocol. mCherry-Parkin (Addgene plasmid 23956) (Narendra et al., 2008), GFP-LC3 (Kabeya et al., 2000) (Dr. Tamotsu Yoshimori gift) and mCherry-GFP-LC3B (Pankiv et al., 2007) (Dr. Terje Johansen gift)

constructs were transfected as previously reported (Bravo-San Pedro et al., 2013).

Transient transfection with PINK1/c-fos siRNA

Cells (1.8×10^5 cells/ml) were transfected with a pair of PINK1 siRNAs (5 nM each), c-fos siRNA (50 nM) or 10 nM scrambled control siRNA (Ambion negative control siRNA #1, Enzo Life Sciences, New York, NY) using HiPerfect transfection reagent (Qiagen, Crawley, UK) (for PINK1 siRNA) or Lipofectamine™ 2000 transfection reagent (Invitrogen, Life Technologies, Carlsbad, CA) (for c-fos siRNA). A combination of PINK1 siRNA pair was used (SI00287931, sense strand: GACGCGUUU CCUCGUUAUGAA; and SI00287924, sense strand: CGGACGCGUJUC UCGUUAU) (Qiagen, Crawley, UK). The c-fos siRNA (SI02781429) had the following sense strand: CCAUAUUAUCUAAGAAATT (Qiagen, Crawley, UK).

Quantitative PCR

Total RNA was extracted from SH-SY5Y cells using the RNeasy Mini Kit (Qiagen, Crawley, UK). cDNA was synthesized by the QuantiTect Reverse Transcription Kit (Qiagen, Crawley, UK), adding 500 ng of template RNA. PINK1 gene expression was measured by quantitative real-time PCR (qPCR) with SYBR Green reagents (Applied Biosystems, Life Technologies, Carlsbad, CA). To normalize the results, housekeeping




Fig. 2. Cytotoxic effect of CCCP. (A) SH-SY5Y cells were exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control) for 24 h, and labeled with Ho to measure the chromatin condensation. Graphic shows percentages of cells with chromatin condensation (# $p > 0.05$; ** $p \leq 0.01$). The arrows highlight nuclei with chromatin condensation. (B) SH-SY5Y cells were exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control) for 24 h, harvested by trypsinization and labeled with PI to measure cell viability by flow cytometry. Percentages of PI-positive cells (# $p > 0.05$; ** $p \leq 0.01$) and representative single-parameter histogram of PI measurement. Data were expressed as mean \pm SEM; events = 10,000.

gene glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression was used. Analysis of relative gene expression was calculated using the comparative threshold ($2^{-\Delta\Delta Ct}$) method (Pfaffl, 2001). Primer sequences were performed as previously described (Gegg et al., 2009).

Western-blotting

Protein was obtained using a lysis buffer composed of 1% (v/v) Triton X-100 in PBS supplemented with protease and phosphatase inhibitors, and quantified according to the CS activity protocol above. Equal amounts of protein (50–75 μ g/condition) were resolved by 4–20% SDS-gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes (Hybond P, GE Healthcare, Chalfont St. Giles, UK) according to a partially modified conventional method (Fuentes et al., 2000). Immunodetection included transferring and blocking the membrane with TBST (Tris-buffered saline with Tween 20) buffer containing 10% non-fat dried milk. Blots were probed with antibodies against PINK1 (clone BC100-494, Novus Biologicals, Southpark Way, Littleton, CO), subunit IV of cytochrome c oxidase (COX IV, ab14744, abcam), prohibitin 1 (#2426, Cell Signaling Technology, Beverly, MA), LC3B (#2775, Cell Signaling Technology, Beverly, MA), p-c-Fos (Ser32) (#5348, Cell Signaling Technology, Beverly, MA), c-Fos (#2250, Cell Signaling Technology, Beverly, MA), β -actin (ab8227, Abcam, Cambridge, UK), α -tubulin (clone TU-02, Santa Cruz Biotechnology, Santa Cruz, CA), Tom20 (clone F-10, Santa Cruz Biotechnology, Santa Cruz, CA), and Lamin A/C (612162, BD Biosciences, Franklin Lakes, NJ). Blots were visualized with respective peroxidase-conjugated secondary antibodies (Bio-Rad, Hercules, CA) and visualized by chemiluminescence




Fig. 3. CCCP effect on PINK1 protein levels over time. (A and B) SH-SY5Y cells were exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control), harvested by trypsinization at different times and lysed. The protein levels of PINK1 were determined by Western-blotting. α -tubulin expression was used as a loading control. (A) Representative blot of at least three independent experiments. (B) Densitometry of each band expressed in arbitrary units of intensity (** $p \leq 0.001$). (C and D) SH-SY5Y cells were transfected with *PINK1* siRNA or scrambled control siRNA for 3 days and treated with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control), harvested by trypsinization at 24 h of treatment. The protein levels of PINK1 were determined by Western-blotting. α -tubulin expression was used as a loading control. (C) Representative blot of at least three independent experiments. (D) Densitometry of each band expressed in arbitrary units of intensity (# $p > 0.05$; *** $p \leq 0.001$). Molecular mass is indicated in kDa next to the blots. Data were expressed as mean \pm SEM; n = 3.

using ECL substrate (Pierce, Thermo Fisher Scientific, Rockford, IL). The β -actin and α -tubulin content was established as loading control, Tom20 as mitochondrial loading control and Lamin A/C as nuclear loading control. The density of bands was determined using ImageJ software (NIH, Bethesda, MD). For quantitative studies, three separate western blots were analyzed.

Mitochondrial isolation

Cell pellets (1×10^7 cells/condition) were washed with PBS supplemented with protease and phosphatase inhibitors and homogenized with a glass-teflon homogenizer in isolation medium (250 mM sucrose, 1 mM EDTA, 10 mM Tris, pH 7.4, supplemented with protease and phosphatase inhibitors). Nuclei were removed by centrifugation at




Fig. 4. Mitochondrial localization of PINK1 in CCCP-treated SH-SY5Y cells. (A–C) SH-SY5Y cells were exposed 24 h with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control), fixed and immunostained for PINK1 (green) and Tom20 (red). (A) Representative immunofluorescence microphotographs. The boxes highlight high intensity of PINK1 and fragmented mitochondria, respectively. (B) Fluorescence intensity per cell (in AU), staining with anti-PINK1 antibody ($\#p > 0.05$; $***p \leq 0.001$). (C) Percentages of cells with fragmented mitochondria, labeled with anti-Tom20 antibody ($\#p > 0.05$; $***p \leq 0.001$). Scale bar represents 10 μ m. Data were expressed as mean \pm SEM; $n = 200$. (D and E) SH-SY5Y cells were immunostained after the treatment and performed with confocal techniques. (D) Representative confocal microphotographs, showing the localization of PINK1 (green) on mitochondria (Tom20; red). (E) Confocal analysis of the mitochondrial localization of PINK1, using Mander's colocalization coefficient ($***p \leq 0.001$). Scale bar represents 10 μ m.

1,500 \times g. A second centrifugation at 12,000 \times g separated cytosolic (supernatant) and mitochondrial fractions, and the pellet was resuspended in isolation medium. Protein concentration was measured using the BCA method, as described in the CS assay.

Flow cytometry

After exposure to different experimental conditions, SH-SY5Y cells were trypsinized and labeled with different fluorochromes. To measure the intracellular calcium levels, cells were incubated with Fluo-3 AM (1 μ M, Molecular Probes, Life Technologies, Carlsbad, CA) for 30 min at 37 $^{\circ}$ C. $\Delta\psi_m$ was assessed with tetramethylrhodamine methyl ester perchlorate (TMRM) (25 nM, Molecular Probes, Life Technologies, Carlsbad, CA) for 30 min at 37 $^{\circ}$ C. Propidium iodide (PI) (1 μ g/ml, Sigma-Aldrich, St. Louis, MO) was used to determine the cell viability (Gonzalez-Polo et al., 2007). PI-negative cells were considered to be viable. Single-parametric analysis was performed with a Cytomics FC500 MPL Flow Cytometer (Beckman Coulter, Miami, FL), which has an argon ion laser operating at 488 nm, with subsequent data analysis using Summit v4.2 software (DakoCytomation, Fort Collins, CO). All measurements were developed in duplicate (10,000 cells/sample) and in at least three independent experiments.

Immunofluorescence

To measure $\Delta\psi_m$ by this technique, cells were washed with PBS and incubated with TMRM for 30 min at 37 $^{\circ}$ C. For the detection of endogenous PINK1 and mitochondrial network, cells were seeded on coverslips, fixed with paraformaldehyde (4% w:v), permeabilized with Triton X-100 solution (Triton X-100 0.2% in PBS) and stained with PINK1 (clone BC100-494, Novus Biologicals, Southpark Way, Littleton, CO) and Tom20 (clone F-10, Santa Cruz Biotechnology, Santa Cruz, CA), then cells were incubated with the respective Alexa Fluor 488 anti-rabbit, 488 anti-mouse and 568 anti-mouse secondary antibodies (Molecular Probes, Life Technologies, Carlsbad, CA). Mitochondrial morphology was determined using ImageJ software. Mitochondria were scored for their circularity, with 0 being a straight line, and 1.0 a perfect circle. In this sense, mitochondria were designated fragmented when the circularity was between 0.60 and 1.00 and tubular when between 0.00 and 0.60. For the transcription factor staining, cells were prepared in the same way, using p-c-Fos (Ser32) (#5348, Cell Signaling Technology, Beverly, MA) and c-Fos (#2250, Cell Signaling Technology, Beverly, MA). The nuclear morphology and chromatin condensation were labeled with Hoechst 33342 (Ho) (2 μ M; Sigma-Aldrich, St. Louis, MO). Cells with condensed nuclei were considered not to be viable. TMRM and Ho staining were analyzed using an inverted fluorescence microscope (IX51, Olympus, Tokyo, Japan) equipped with a camera (DP70, Olympus, Tokyo, Japan). The colocalization of PINK1 with mitochondria and nuclear c-Fos, images were taken with a confocal scanning laser (Nikon A1, Tokyo, Japan) coupled to an inverted microscope (Eclipse Ti, Nikon, Tokyo, Japan). The quantitative measurement of the fluorescence signal was performed using ImageJ software. For the colocalization studies, the samples were quantified using the JaCoP plug-in for ImageJ, based in Mander's coefficient (Bolte and Cordelieres, 2006), analyzing at least 30 cells for each condition. For the other measurements, we counted at least 200 cells per condition. In the nuclear colocalization experiments, pictures were converted into "6_shades" LUT, setting in ImageJ software.

Measurement of intracellular calcium

To perform calcium measurements, cells were seeded at a density of 1×10^6 cells/ml on coverslips of 14 mm. Cells were loaded with Fura-2 AM (5 μ M, Molecular Probes, Life Technologies, Carlsbad, CA) for 45 min at 37 $^{\circ}$ C in Locke's K25 buffer that contained 137 mM NaCl, 5 mM KCl, 4 mM NaHCO₃, 2 mM CaCl₂, 1 mM MgCl₂, 5 mM glucose, and 10 mM HEPES, pH 7.4, and then washed three times with Locke's K25 buffer at 37 $^{\circ}$ C to remove extracellular Fura-2 AM. Fura-2 was excited alternatively at 340 nm and 380 nm, and emitted at 510 nm using an illumination system (MT20, Olympus, Tokyo, Japan). The ratio of fluorescent signals obtained at 340 nm and 380 nm excitation wavelengths was recorded at 2 second intervals during 10–15 min, depending on the experiment. F340/F380 ratio was used to represent the $[Ca^{2+}]_i$ in the cells. The fluorescence of Fura-2-loaded SH-SY5Y cells was monitored and acquired with a CCD camera (Hamamatsu Orca-ER, Shizuoka, Japan) for ratiometric imaging, mounted on an inverted microscope (IX81, Olympus, Tokyo, Japan). Images were analyzed using the software Cell'R (Olympus, Tokyo, Japan). Fields of cells and regions of interest (ROIs) were chosen based on homogenous and equal cell densities. For the calcium channel blockers (nifedipine and ω -CTX), cells were treated before they were measured as was described in treatments. All the experiments were performed at 37 $^{\circ}$ C.

Nuclear isolation

Nuclear and cytoplasmic fractions were obtained from cell lysates (1×10^7 cells/condition), using the EpiQuikTM Nuclear Extraction Kit (Epigentek, Farmingdale, NY). Protein concentration was determined by the BCA method assay, how it is detailed in the CS measurement.




Fig. 5. CCCP-induced mitophagy is parallel to mitochondrial PINK1 localization. (A and B) SH-SY5Y cells were exposed with 10 μ M CCCP or with vehicle (0.05% (v/v) ethanol), harvested by trypsinization at different times, mitochondria isolated and Western-blotting performed. Blots were probed with antibodies against PINK1 and LC3B. α -tubulin and Tom20 were used as a cytosolic and mitochondrial loading control, respectively. (A) Representative blot of at least three independent experiments. (B) Densitometry of each band expressed in arbitrary units of intensity ($***p \leq 0.001$). Molecular mass is indicated in kDa next to the blots. (C–F) SH-SY5Y cells were transfected with mCherry-Parkin or GFP-LC3 and exposed 6, 12 or 24 h with 10 μ M CCCP or with vehicle (0.05% (v/v) ethanol), fixed and immunostained for Tom20 (green/red). (C and D) Representative immunofluorescence microphotographs of 6 hour treated-cells. The boxes highlight mitochondrial localization of mCherry-Parkin and GFP-LC3, respectively. (E) Percentages of cells with mCherry-Parkin on mitochondria, labeled with anti-Tom20 antibody ($***p \leq 0.001$). (F) Percentages of cells with GFP-LC3 on mitochondria, labeled with anti-Tom20 antibody ($***p \leq 0.001$). Scale bar represents 10 μ m.

Statistical analyses

Each experiment was repeated at least three times, with a satisfactory correlation between the results of individual experiments. The data shown are those of a representative experiment; each group was the average of three to four culture dishes. In each experiment, the differences between groups were assessed by appropriate statistical methods. Specifically, statistical significance was evaluated with two-tailed unpaired Student's *t*-test and ANOVA test, and all comparisons with *p* value less than 0.05 ($p < 0.05$) were considered statistically significant. The data are expressed as the mean \pm SEM. All data were analyzed with SPSS Statistics 20 (IBM, Chicago, IL) for Windows.

Results

Mitochondrial damage and autophagy induction by CCCP

CCCP is a lipid-soluble weak acid, which acts as a very powerful mitochondrial uncoupling agent that carries protons across the mitochondrial inner membrane, thereby diminishing the proton gradient. To investigate the molecular events in CCCP-induced depolarization, according to previous reports (D. Narendra et al., 2010; D.P. Narendra et al., 2010; Vives-Bauza et al., 2010), cells were treated with 10 μ M CCCP. The mitochondrial content in SH-SY5Y cells was assessed by measuring the CS activity (Gegg et al., 2010; Wood-Kaczmar et al., 2008). CCCP treatment produced a significant decrease in mitochondrial mass ($29.2 \pm 3.1\%$) (mean \pm standard deviation [SD]) after 24 h (Fig. 1A), meanwhile a short exposure (3 h) did not result in decreased mitochondrial content. Furthermore, washing away of CCCP after 6 h of

treatment, and measuring mitochondrial content 18 h later (24 h after start of treatment), no longer resulted in a significant decrease in mitochondrial content (data not shown). The decrease in CS activity was not due to a failure of the enzyme being imported in to mitochondria because of a lack of mitochondrial membrane potential, as we have previously shown that (a) knockdown of *PINK1* or *parkin* reverses the decrease in CS activity following CCCP treatment and (b) CS loss was greater in SH-SY5Y over expressing *parkin*, when compared to SH-SY5Y cells with endogenous Parkin levels (Gegg et al., 2010).

To further prove that the decrease of CS activity after 24 h of CCCP treatment was due to the loss of mitochondria, we analyzed mitochondrial protein levels by Western-blotting, checking two inner mitochondrial membrane proteins, COX IV and prohibitin 1. CCCP treatment for 24 h caused a 61% reduction in prohibitin 1 and a 22% reduction in COX IV (Figs. 1B and C), reflecting the fall in mitochondrial content. To prove that CCCP produced $\Delta\psi_m$ reduction, we measured TMRM in SH-SY5Y by immunofluorescence. In this sense, CCCP-treated cells shown a $\Delta\psi_m$ dissipation at 24 h (10.5 ± 5.1 arbitrary units (AU) of TMRM fluorescence intensity/cell), when compared with untreated cells (37.6 ± 5.1 AU) or vehicle-treated cells (35.6 ± 8.1 AU) (Figs. 1D and E). This $\Delta\psi_m$ decrease was observed after 1 hour CCCP exposure (data not shown), and we confirmed this result by flow cytometry (data not shown).

To confirm that CCCP is inducing autophagy in our cell model, and thereby the mechanism by which mitochondria are being degraded, we analyzed the autophagic protein LC3. LC3 presents as a cytosolic form (called LC3-I), which can then be conjugated to phosphatidylethanolamine to generate LC3-phosphatidylethanolamine conjugate (LC3-II), that is then recruited to autophagosomes. An increase in LC3-II




Fig. 6. Increase of *PINK1* gene expression, and not its stabilization with chaperones, after the CCCP exposure. (A) SH-SY5Y cells were exposed with 10 μ M CCCP or with vehicle (0.05% (v/v) ethanol) at different times, and *PINK1* mRNA levels measured by reverse transcription and quantitative PCR. Relative expression was determined using GAPDH as housekeeping gene (# $p > 0.05$; ** $p \leq 0.01$; *** $p \leq 0.001$). (B and C) SH-SY5Y cells were preincubated 1 h with 5 μ g/ml Act. D, 100 μ g/ml CHX or vehicle (0.1% (v/v) DMSO), exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control) for 24 h, harvested by trypsinization and lysed. The protein levels of PINK1 were determined by Western blotting. α -tubulin expression was used as a loading control. (B) Representative blot of at least three independent experiments. (C) Densitometry of each band expressed in arbitrary units of intensity (# $p > 0.05$; *** $p \leq 0.001$). (D–F) SH-SY5Y cells were preincubated 1 h with 5 μ M MG-132 or 100 nM Baf. A1, exposed with 10 μ M CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control) for 24 h, incubated with 1 μ M 17-AAG 3 h before collecting cells, harvested by trypsinization and lysed. The protein levels of PINK1 and COX IV were determined by Western blotting. α -tubulin expression was used as a loading control. (D) Representative blot of at least three independent experiments. (E) Densitometry of each band expressed in arbitrary units of intensity (# $p > 0.05$; *** $p \leq 0.001$). (F) Densitometry of each band expressed in arbitrary units of intensity (# $p > 0.05$; *** $p \leq 0.001$). Molecular mass is indicated in kDa next to the blots. Data were expressed as mean \pm SEM; $n = 3$.

protein levels can be used as a marker of autophagosome formation. In this sense, we observed that the ratio between both isoforms (LC3-II/LC3-I) increased in CCCP-treated cells in a time-dependent manner, peaking at 12 h treatment (Figs. 1F and G). To affirm that autophagic flux is active, we measured LC3 turnover by lysosomes, using the mCherry-GFP-LC3B plasmid (GFP fluorescence is quenched by the lower pH levels in autophagolysosomes, whereas mCherry fluorescence is not). The presence of the uncoupler increased the number of red puncta (mCherry-LC3B) and, therefore, the autophagolysosomes over time ($21.0 \pm 3.1\%$ and $80.3 \pm 10.0\%$ at 3 and 24 h of CCCP treatment, respectively), whereas GFP did not accumulate (Figs. 1H and I). This confirms that the increase in LC3-II protein levels seen after CCCP treatment (Figs. 1F and G) was due to increased autophagy flux.

Cytotoxic effect of CCCP

To evaluate if this mitochondrial uncoupler could induce cell death, we measured typical patterns such as chromatin condensation and nuclear membrane permeabilization. Nuclei of untreated and vehicle-treated cells had no morphologic changes, while CCCP exposure increased the number of nuclei with chromatin condensation

($24.9 \pm 3.0\%$) (Fig. 2A) and positive PI staining ($19.3 \pm 4.5\%$) 24 h after treatment (Fig. 2B).

CCCP effect on PINK1 protein levels

To further investigate the role of PINK1 in the mitochondrial damage, we determined the levels of PINK1 protein after CCCP exposure, demonstrating how the presence of the uncoupler produced a gradual and significant accumulation of endogenous FL-PINK1 protein in a time-dependent manner (Figs. 3A and B). Noticeably, the significant increase in FL-PINK1 after 24 h of CCCP treatment occurred at a time when mitochondrial content was decreased (Figs. 1A–C). Proteolytically processed forms of PINK1 (Δ N-PINK1) were undetectable in CCCP-treated cells. FL-PINK1 was not observed in untreated or vehicle-treated cells. However, FL-PINK1 levels fell within 15 min of CCCP washout, suggesting that its presence depends on the mitochondrial depolarization (data not shown). To confirm that the band detected was FL-PINK1, we silenced *PINK1* expression (Figs. 3C and D) or over-expressed full-length wild-type *PINK1* without a tag (data not shown).




Fig. 7. Involvement of extracellular calcium in PINK1 levels. (A–D) Time courses of Ratio (F340/F380) in Fura-2 AM loaded SH-SY5Y cells to determine cytosolic calcium changes. (A) Time course of $[Ca^{2+}]_{cyt}$ changes in SH-SY5Y cells after the addition of 10 μ M CCCP in Ca^{2+} -free Locke's K25 buffer. (B) Time course of $[Ca^{2+}]_{cyt}$ changes in SH-SY5Y cells induced by 10 μ M CCCP in complete Locke's K25 buffer (***) $p \leq 0.001$ between + Ca^{2+} -CCCP-treated ($n = 22$) and - Ca^{2+} -CCCP-treated cells ($n = 12$). (C) Time course of $[Ca^{2+}]_{cyt}$ changes in SH-SY5Y cells after the treatment of 10 μ M nifedipine and 10 μ M CCCP in complete Locke's K25 buffer (*) $p \leq 0.05$ between + Ca^{2+} -nifedipine-CCCP-treated ($n = 10$) and + Ca^{2+} -CCCP-treated cells). (D) Time course of $[Ca^{2+}]_{cyt}$ changes in SH-SY5Y cells in the presence of 2 μ M ω -CTX and 10 μ M CCCP in complete Locke's K25 buffer (***) $p \leq 0.01$ between + Ca^{2+} - ω -CTX-CCCP-treated ($n = 31$) and + Ca^{2+} -CCCP-treated cells). (E and F) SH-SY5Y cells were preincubated 1 h with 5 μ M BAPTA-AM, exposed with 10 μ M CCCP or with vehicle (0.05% (v/v) ethanol), harvested by trypsinization at different times and lysed. The protein levels of PINK1 were determined by Western-blotting. α -tubulin expression was used as a loading control. (E) Representative blot of at least three independent experiments. (F) Densitometry of each band expressed in arbitrary units of intensity (# $p > 0.05$; * $p \leq 0.05$; *** $p \leq 0.001$). (G and H) SH-SY5Y cells were preincubated 1 h with 5 μ M BAPTA-AM, exposed 6 or 24 h with 10 μ M CCCP or with vehicle (0.05% (v/v) ethanol), mitochondria isolated and Western-blotting performed. Tom20 was used as a mitochondrial loading control. (G) Representative blot of at least three independent experiments. (H) Densitometry of each band expressed in arbitrary units of intensity (** $p \leq 0.01$; *** $p \leq 0.001$). Molecular mass is indicated in kDa next to the blots. Data were expressed as mean \pm SEM; $n = 3$.

CCCP-induced mitophagy is due to mitochondrial PINK1 localization

We next examined the subcellular localization of PINK1, analyzing by immunofluorescence endogenous PINK1 and co-staining mitochondria with Tom20, an outer mitochondrial membrane protein. In control and vehicle-treated cells for 24 h, endogenous PINK1 levels were low (1.2 ± 0.4 AU of PINK1 fluorescence intensity/cell in control and 1.8 ± 0.3 in vehicle-treated cells) and mitochondria showed the typical tubular structure ($3.2 \pm 2.9\%$ of cells with fragmented mitochondria in control and $5.9 \pm 4.3\%$ in vehicle-treated cells). Meanwhile, in CCCP-treated cells, levels of PINK1 increased (4.4 ± 1.0 AU of fluorescence intensity/cell) (Figs. 4A and B) and the mitochondrial network was fragmented ($92.1 \pm 4.8\%$) (Figs. 4A and C), showing how there is an accumulation of PINK1 in these cells co-localized with damaged mitochondria (Figs. 4D and E) (0.54 ± 0.09 Mander's colocalization coefficient in CCCP-treated cells compared to 0.15 ± 0.05 in vehicle-treated cells).

Furthermore, we observed that PINK1 levels increased in the mitochondria-rich fraction in a time-dependent manner after CCCP treatment, whereas in the cytosolic-rich fraction no band was observed

(Figs. 5A and B). We also noted that there was an increase in LC3-II levels in the mitochondria rich fraction following CCCP treatment, being higher at 12 h (Figs. 5A and B). We confirmed this mitochondrial localization of LC3 by immunofluorescence, using GFP-LC3 plasmid (Figs. 5D and F). As with previous reports, accumulation of Parkin on mitochondria following CCCP treatment occurred. However, while PINK1 continued to accumulate on damaged mitochondria after 24 h, the amount of Parkin did not follow the same pattern (Figs. 5C and E), decreasing at this time, as LC3 protein (Figs. 5A, B, D and F).

Increased PINK1 gene expression after the CCCP exposure

We assessed whether the increase of endogenous PINK1 in mitochondria after CCCP treatment was due to an increase in gene expression level or a possible chaperone-mediated stabilization. For this purpose, we measured the mRNA levels of PINK1 by qPCR. In a short period of time (3 h), there were no differences, but we observed a significant increase of the PINK1 mRNA in a time-dependent manner, and was significantly higher at 6 (1.76 ± 0.22 times more than vehicle-treated cells at 3 h) and 24 h after CCCP treatment (4.01 ± 0.66 times




Fig. 8. *PINK1* calcium-dependent gene expression. (A and B) SH-SY5Y cells were preincubated 1 h with 5 μ M BAPTA-AM or 500 μ M EGTA, exposed 6 or 24 h with 10 μ M CCCP or with vehicle (0.05% (v/v) ethanol), and *PINK1* mRNA levels measured by reverse transcription and quantitative PCR. Relative expression was determined using GAPDH as housekeeping gene antibody. (A) Relative *PINK1* mRNA expression after 6 hour CCCP exposure and calcium chelation ($***p \leq 0.001$). (B) Relative *PINK1* mRNA expression after 24 hours of CCCP treatment and calcium chelation ($\#p > 0.05$). (C and D) SH-SY5Y cells were preincubated 1 h with 5 μ M BAPTA-AM or 500 μ M EGTA, exposed 24 h with 10 μ M CCCP, harvested by trypsinization and lysed. The protein levels of *PINK1* were determined by Western-blotting. α -tubulin expression was used as a loading control. (C) Representative blot of at least three independent experiments. (D) Densitometry of each band expressed in arbitrary units of intensity ($*p \leq 0.05$; $***p \leq 0.001$). Molecular mass is indicated in kDa next to the blots. Data were expressed as mean \pm SEM; $n = 3$.

more than vehicle-treated cells at 3 h (Fig. 6A). These results were consistent when we studied the blockade of transcription and translation, using Act. D and CHX, respectively. The treatment with both inhibitors abolished expression of endogenous FL-*PINK1* protein (Figs. 6B and C).

Also, we investigated if degradation mechanisms, such as UPS and autophagy, modified *PINK1* protein levels using MG-132 and Baf. A1, respectively. In this sense, there was an accumulation of Δ N-*PINK1*, but not FL-*PINK1*, in untreated and vehicle-treated cells after the treatment of MG-132, as previously reported (Lin and Kang, 2008; Takatori et al., 2008). Following CCCP treatment, Δ N-*PINK1* levels were decreased, which was expected as FL-*PINK1* accumulates on the outer mitochondrial membrane, thus reducing the amount of *PINK1* available for cleavage by proteases in the inner mitochondrial membrane. In contrast, the levels of FL-*PINK1* were further increased when we treated cells with CCCP and inhibited the autophagy mechanism with Baf. A1 (blocking autophagosome/lysosome fusion) (Figs. 6D and E). Western-blotting for COX IV and LC3-II protein levels indicated

that Baf. A1 prevented the CCCP-induced decrease in mitochondrial content (Figs. 6D and F) and inhibited autophagy flux (Fig. S1). This suggests that the further increase in FL-*PINK1* levels after CCCP and Baf. A1 treatment was most likely due to a greater number of mitochondria on which *PINK1* could accumulate. Finally, FL-*PINK1* protein was still increased by CCCP in the presence of 17-AAG, an inhibitor of Hsp90 (Figs. 6D and E), further suggesting that the increase of FL-*PINK1* at 24 h was due to de novo synthesis, rather than increased stabilization of *PINK1* (Lin and Kang, 2008).

Involvement of extracellular calcium in *PINK1* levels

To examine whether the treatment with CCCP stimulated calcium signaling and if this is associated with increased transcription of *PINK1*, leading to the accumulation of FL-*PINK1* on mitochondria, we measured intracellular calcium mobilization in SH-SY5Y cells using the ratiometric indicator Fura-2 AM. We found that the presence of CCCP did not modify the release of calcium from an intracellular store (Fig. 7A), but produced the entry of extracellular calcium and consequently an elevation in cytosolic calcium levels immediately after treatment (Fig. 7B). Next, we evaluated the mechanism of extracellular calcium entry. We investigated whether calcium entry was dependent on L- and N-type VDCCs, which are well characterized in SH-SY5Y cells (Zhang et al., 2009) and have been implicated in PD pathogenesis (Goldberg et al., 2012; Ilijic et al., 2011). We used 10 μ M nifedipine and 2 μ M ω -CTX, and showed that the treatment with these VDCC blockers significantly reduced extracellular calcium entry (Figs. 7C and D). Moreover, the blockade of intracellular calcium release from stores such as ER (using thapsigargin), mitochondria (with rotenone) and lysosomes (using Baf. A1) did not prevent the initial increase in intracellular calcium observed after treatment with CCCP (data not shown).

Next, we analyzed the role of this intracellular calcium elevation after the CCCP treatment on the *PINK1* levels and its possible importance in the *PINK1* mitochondrial localization. We observed that calcium chelation with BAPTA-AM decreased FL-*PINK1* levels after CCCP treatment, both in cell lysates (Figs. 7E and F) and isolated mitochondria (Figs. 7G and H). Chelation of calcium by BAPTA-AM was confirmed by flow cytometry (Fig. S2). Furthermore, to assess whether cytosolic calcium increase could mimic the CCCP effects on *PINK1* protein, cells were exposed to the calcium ionophore ionomycin and the L-type VDCC agonist Bay K 8644, showing that both did not modify FL-*PINK1* protein levels, comparable to vehicle-treated cells (Fig. S3).

PINK1 calcium-dependent gene expression

To elucidate if extracellular calcium increases the *PINK1* mitochondrial localization by enhancing its gene expression, *PINK1* mRNA levels were measured by qPCR. *PINK1* mRNA levels were significantly decreased after 6 h of CCCP treatment when cytosolic calcium was eliminated by BAPTA-AM (0.69 ± 0.09 times less than 6 hour CCCP-treated cells) or extracellular calcium in the medium was chelated by EGTA (0.77 ± 0.10 times less than 6 hour CCCP-treated cells) (Fig. 8A). But, if the exposure is longer (24 h), these rates did not modulate when we sequestered cytosolic (0.18 ± 0.25 times less than CCCP-treated cells) and extracellular calcium (0.09 ± 0.62 times less than CCCP-treated cells) (Fig. 8B). However, it would appear that decreased transcription of *PINK1* mRNA by BAPTA-AM or EGTA for at least 6 h was sufficient to decrease FL-*PINK1* protein levels after 24 h of CCCP treatment (Figs. 7E–H, 8C and D).

Nuclear recruitment and activation of *c-Fos* after the CCCP treatment

To further evaluate the role of calcium in *PINK1* expression, we performed some experiments to elucidate whether this higher gene expression under CCCP treatment is modulated by a transcription factor, following activation by calcium. Bioinformatic analysis of the *PINK1*




Fig. 9. Nuclear recruitment of c-Fos after the CCCP treatment. (A and B) SH-SY5Y cells were exposed with 10 μM CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control), harvested by trypsinization at different times and lysed. The protein levels of p-c-Fos (Ser32) and c-Fos were determined by Western-blotting. α-tubulin expression was used as a loading control. (A) Representative blot of at least three independent experiments. (B) Densitometry of each band expressed in arbitrary units of intensity (#p > 0.05; *p ≤ 0.05; **p ≤ 0.01). (C–F) SH-SY5Y cells were exposed 3 h with 10 μM CCCP or with vehicle (0.05% (v/v) ethanol), fixed and immunostained for p-c-Fos (Ser32) or c-Fos (green) and Ho (blue). (C) Representative immunofluorescence microphotographs. The arrows highlight high nuclear intensity of p-c-Fos (Ser32). (D) Representative immunofluorescence microphotographs. The arrows highlight c-Fos nuclear staining. (E) Nuclear fluorescence intensity per cell (in AU), staining with anti-p-c-Fos (Ser32) antibody (***p ≤ 0.001). (F) Percentages of cells with nuclear c-Fos (***p ≤ 0.001). Scale bar represents 10 μm. Data were expressed as mean ± SEM; n = 200. (G and H) SH-SY5Y cells were exposed 3 h with 10 μM CCCP, with vehicle (0.05% (v/v) ethanol) or without any treatment (control), nuclear isolated and Western-blotting performed. Lamin A/C was used as a nuclear loading control. (G) Representative blot of at least three independent experiments. (H) Densitometry of each band expressed in arbitrary units of intensity (***p ≤ 0.001). Molecular mass is indicated in kDa next to the blots. Data were expressed as mean ± SEM; n = 3.

promoter indicated four c-Fos response elements (Fig. S4). We observed that CCCP treatment increased the phosphorylation of c-Fos at residue Ser32 between 3 and 6 h, when compared with cells treated with the vehicle (Figs. 9A and B). Immunofluorescence of c-Fos also showed that CCCP treatment produced higher levels of p-c-Fos (Ser32) (7.06 ± 2.85 AU of nuclear fluorescence intensity/cell), compared to vehicle-treated cells (2.84 ± 1.27 AU) (Figs. 9C and E). The nuclear localization of c-Fos was also increased by CCCP treatment (58.22 ± 11.02% of CCCP-treated cells vs. 11.36 ± 5.80% of vehicle-treated cells) (Figs. 9D and F). The nuclear translocation of c-Fos was also confirmed by Western-blotting (Figs. 9G and H). We analyzed other factors modulated by calcium, such as CREB, c-Jun, FOXO3a and NFκB, but obtained inconclusive results (data not shown).

c-Fos calcium-dependent signaling acts in parallel to PINK1 expression after CCCP exposure

To elucidate if extracellular calcium enhanced PINK1 expression via c-Fos activation, firstly, we analyzed the phosphorylation of c-Fos after a combination of CCCP exposure and deprivation of cytosolic or extracellular calcium. Both BAPTA-AM and EGTA treatment with CCCP decreased phosphorylation of c-Fos (Figs. 10A and B). Finally, we set out to determine whether the c-Fos/PINK1 axis was in the same pathway. Following c-fos gene silencing, PINK1 protein levels did not change

(Figs. 10E and F) after the 24 h CCCP treatment, and vice versa, the silencing of PINK1 did not affect the c-Fos phosphorylation, that appeared when cells were exposed to uncoupler for 3 h (Figs. 10C and D). Further studies are needed to elucidate which mechanisms control PINK1 gene expression.

CCCP-induced mitophagy is calcium-dependent, but is a c-Fos independent mechanism

At this point, we considered whether mitophagy could be modulated by calcium and/or c-Fos signaling. SH-SY5Y cells treated with CCCP and BAPTA-AM or EGTA increased COX IV protein levels, when compared to cells treated with CCCP alone. However, LC3 protein levels were increased to a similar extent in cells treated with CCCP alone, or in combination with BAPTA-AM or EGTA (Figs. 11A and B). Moreover, if we analyzed LC3 and COX IV levels after the c-fos gene silencing, we observed the same pattern as the Lipofectamine condition (Figs. 11C and D), showing how this reagent generates an accumulation of LC3-II protein levels (Mo et al., 2012).

Discussion

We report that depolarization of mitochondria with CCCP in SH-SY5Y cells results in a calcium-dependent increase in transcription of




Fig. 10. c-Fos-independent expression of *PINK1* after CCCP exposure. (A and B) SH-SY5Y cells were preincubated 1 h with 5 μ M BAPTA-AM or 500 μ M EGTA, exposed 3 h with 10 μ M CCCP, harvested by trypsinization and lysed. The protein levels of p-c-Fos (Ser32) were determined by Western-blotting. α -tubulin expression was used as a loading control. (A) Representative blot of at least three independent experiments. (B) Densitometry of each band expressed in arbitrary units of intensity ($***p \leq 0.001$). (C–F) SH-SY5Y cells were transfected with *c-fos* siRNA, *PINK1* siRNA or scrambled control siRNA for 2 days and treated with 10 μ M CCCP, harvested by trypsinization at different times and lysed. The protein levels of p-c-Fos (Ser32), c-Fos and *PINK1* were determined by Western-blotting. α -tubulin expression was used as a loading control. (C) Representative blot of at least three independent experiments, from 3 hour-CCCP-treated cells. (D) Densitometry of each band expressed in arbitrary units of intensity ($\#p > 0.05$; $***p \leq 0.001$). (E) Representative blot of at least three independent experiments, from 24 hour-CCCP-treated cells. (F) Densitometry of each band expressed in arbitrary units of intensity ($\#p > 0.05$; $***p \leq 0.001$). Molecular mass is indicated in kDa next to the blots. Data were expressed as mean \pm SEM; $n = 3$.

PINK1, and not just stabilization of *PINK1* protein on the outer mitochondrial membrane. Previously, it has been shown that FL-*PINK1* accumulates on the outer mitochondrial membrane of mitochondria within 15 min (Matsuda et al., 2010; D.P. Narendra et al., 2010; Shiba-Fukushima et al., 2012). Similar to these previous reports, we also found that the accumulation of FL-*PINK1* was diminished after 15 min of CCCP being removed, presumably because upon restoration of the mitochondrial membrane potential, FL-*PINK1* was able to proceed to the inner mitochondrial membrane to be processed by mitochondrial proteases (Deas et al., 2011; Greene et al., 2012; Jin et al., 2010) and then be degraded by the proteasome (Jin et al., 2010; Lin and Kang, 2008; Takatori et al., 2008).

These reports have typically looked at FL-*PINK1* protein levels up to 6 h after CCCP treatment. However, we are not aware of any reports of *PINK1* mRNA levels following CCCP treatment. We found that *PINK1* mRNA levels were significantly increased after 6 h of CCCP treatment and continued to rise for 24 h. This resulted in a continued increase in de novo FL-*PINK1* protein, which accumulated on mitochondria. The increase in FL-*PINK1* protein at the mitochondria after 24 h occurred despite a 29% decrease in mitochondrial content. This highlights the importance of *PINK1* on damaged mitochondria. It should be noted that we found that washing away of CCCP after 6 h, and measuring mitochondrial content 18 h later (24 h in total), no longer resulted in a significant decrease in mitochondria content. This is despite the fact that the recruitment of Parkin to mitochondria by *PINK1* (Matsuda et al., 2010; D.P. Narendra et al., 2010; Vives-Bauza et al., 2010), and the *PINK1*/Parkin-dependent ubiquitination of mitochondrial proteins such as VDAC and the mitofusins, and the mitochondrial transport protein Miro, occurred within 3 h of mitophagy induction (Chan et al., 2011; Gegg et al., 2010; Geisler et al., 2010; Tanaka et al., 2010). Our results suggest that maximum activity of mitophagy (as measured by

colocalization of LC3 with mitochondria) occurred at 12 h of CCCP treatment, meanwhile mitochondrial *PINK1* localization continued increasing for at least 24 h. This suggests that FL-*PINK1* might have further functions in mitochondrial quality control downstream of the recruitment of Parkin and ubiquitination of mitochondrial proteins.

Higher *PINK1* expression could be linked with a compensatory increase in mitochondrial biogenesis. The induction of mitophagy would require the cell to initiate synthesis of new mitochondria to replace them. *PINK1* has been linked with mitochondrial biogenesis, with knockdown of *PINK1* in SH-SY5Y cells decreasing mtDNA levels and mtDNA synthesis (Gegg et al., 2009). Induction of mitochondrial uncoupling proteins can induce mitochondrial biogenesis via the transcription factor Nrf1 (Li et al., 1999). Therefore it is unclear whether any putative increase in mitochondrial biogenesis following CCCP treatment is a direct response to mitochondrial uncoupling or the removal of mitochondria.

This increase in transcription appeared to be due to an increase in intracellular calcium levels. Treatment of SH-SY5Y cells with CCCP increased calcium levels within the cell, with uptake of calcium into cells via the L- and N-type VDCCs as a major component. In this sense, higher levels of intracellular calcium after FCCP (CCCP analog) exposure are reduced in calcium-free solution or by VDCC blockade (Buckler and Vaughan-Jones, 1998; Sato, 1997). More sensitive techniques are required to determine if small local increases in cytosolic calcium could also be caused as a result of increased mitochondrial release upon depolarization (Tonkikh and Carlen, 2009). The increase in *PINK1* expression did not occur when intracellular calcium was increased by ionomycin or an L-VDCC agonist. Ionomycin treatment has previously been shown not to result in the phosphorylation of Ser65 of Parkin by *PINK1*, an early event in mitophagy (Kondapalli et al., 2012). We suspect that we did not see the increase in *PINK1* transcription




Fig. 11. Mitophagy decreases after calcium chelation, but is a c-Fos-independent mechanism. (A and B) SH-SY5Y cells were preincubated 1 h with 5 μ M BAPTA-AM or 500 μ M EGTA, exposed 24 h with 10 μ M CCCP, harvested by trypsinization and lysed. The ratio LC3-II/LC3-I and protein levels of COX IV were determined by Western-blotting. α -tubulin expression was used as a loading control. (A) Representative blot of at least three independent experiments. (B) Densitometry of each band expressed in arbitrary units of intensity (# $p > 0.05$; ** $p \leq 0.01$). (C and D) SH-SY5Y cells were transfected with *c-fos* siRNA, *PINK1* siRNA or scrambled control siRNA for 2 days and treated 24 h with 10 μ M CCCP, harvested by trypsinization and lysed. The ratio LC3-II/LC3-I and protein levels of COX IV were determined by Western-blotting. α -tubulin expression was used as a loading control. (C) Representative blot of at least three independent experiments. (D) Densitometry of each band expressed in arbitrary units of intensity (# $p > 0.05$). Molecular mass is indicated in kDa next to the blots. Data were expressed as mean \pm SEM; $n = 3$.

with these two treatments because the mitochondria were still healthy, and were thus still able to buffer the calcium overload generated by ionophores or the L-VDCC agonist. While treatment with calcium chelators prevented loss of mitochondrial content following 24 h of CCCP treatment, further work is required to determine whether this is directly due to the decrease in *PINK1* transcription, or other effects of decreased calcium on other components of the autophagy machinery.

Therefore, the induction of *PINK1* expression might simply be a protective measure against the increased cytosolic calcium observed after CCCP treatment. Indeed, there was an increase in nuclear condensation and PI-positive cells following 24 h of CCCP treatment. *PINK1* expression is known to protect against a variety of stressors including staurosporine, MPTP and oxidative stress (Gegg et al., 2009; Haque et al., 2008; Wood-Kaczmar et al., 2008). Deregulation of mitochondrial calcium homeostasis is also associated with loss of *PINK1* function (Abramov et al., 2011; Akundi et al., 2011; Gandhi et al., 2009; Heeman et al., 2011), suggesting that increased mitochondrial

localization of *PINK1* could lead to maintain functional interactions, activating channels and transporters along the mitochondrial network such as mPTP and NCXmito, to regulate calcium homeostasis and for instance, minimize potential excitotoxic effects. Very recently, a report has shown that *PINK1* could prevent mitochondrial calcium overload through the activation of isoforms NCX2 and NCX3 (Wood-Kaczmar et al., 2013). Related to this, the Parkin mitochondrial localization enhances ER-mitochondria crosstalk, favoring the calcium transfer (Cali et al., 2013). Moreover, our results suggest that calcium overload could be necessary for the mitochondrial removal by *PINK1*/Parkin-mediated mitophagy (Narendra et al., 2008; D.P. Narendra et al., 2010).

The identity of the transcription factor responsible for the increased *PINK1* transcription is unknown. FOXO3a increased *PINK1* transcription in T-lymphocytes, MCF7 and SH-SY5Y cells upon growth factor/serum deprivation (Mei et al., 2009). *PINK1* transcription was also no longer increased following ischemia in FOXO1 and FOXO3 knock-out mice (Sengupta et al., 2011). However there was no evidence of FOXO3a increasing *PINK1* transcription following treatment with CCCP. In this report, while we found that c-Fos translocated to the nucleus upon CCCP exposure, this had no effect on *PINK1* protein levels. It is well-known that c-Fos is activated after pathological situations, such as hypoxia or ischemia (Cho et al., 2001), mediated by L- and N-type VDCCs (Premkumar et al., 2000; Zhao et al., 2007), so related to our results, c-Fos might be involved in adaptive responses upon calcium overload and mitochondrial depolarization promoting neuronal survival.

Conclusions

This study shows that treatment of SH-SY5Y cells with CCCP increases *PINK1* gene expression for at least 24 h, leading to a large accumulation of *PINK1* protein on damaged mitochondria. This increase was calcium-dependent and might be via an influx of calcium via L- and N-type VDCCs, allowing for the mitochondrial removal by mitophagy. Moreover, the transcription factor c-Fos was activated by calcium, although was not responsible for induction of *PINK1* transcription. The induction of *PINK1* expression and activation of c-Fos could be a mechanism by which the cell activates neuroprotective mechanisms that might result in restoring calcium homeostasis and/or promote mitochondrial biogenesis (Fig. 12).

Abbreviations

Act. D	actinomycin D
AP-1	activator protein-1
Baf. A1	bafilomycin A1
BAPTA-AM	1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester
BSA	bovine serum albumin
c-Fos	FBJ murine osteosarcoma viral oncogene homolog
CCCP	carbonyl cyanide m-chlorophenylhydrazone
CHX	cycloheximide
CREB	cyclic AMP response element binding protein
CS	citrate synthase
$\Delta\psi_m$	mitochondrial membrane potential
EGTA	ethylene-bis(oxyethylenitrilo)tetraacetic acid tetrasodium
ER	endoplasmic reticulum
FCCP	carbonyl cyanide p-trifluoromethoxyphenylhydrazone
GAPDH	glyceraldehyde 3-phosphate dehydrogenase
Ho	Hoechst 33342
kDa	kilodaltons
LC3	microtubule-associated protein 1 light chain 3
mCU	mitochondrial uniporter
MG-132	carbobenzoxyl-leucyl-leucyl-leucinal
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mPTP	mitochondrial permeability transition pore
NCXmito	mitochondrial Na ⁺ /Ca ²⁺ exchanger
NF- κ B	nuclear factor- κ B




Fig. 12. Schematic representation of CCCP effect in SH-SY5Y cells and the interplay between PINK1 and calcium. In physiological situations, $\Delta\psi_m$ is high, so FL-PINK1 is processed in mitochondria by proteases, including PARL. The cleaved isoforms are then degraded by UPS. However, when cells are exposed to CCCP, calcium influx through L- and N-type VDCCs increase PINK1 gene expression, leading higher levels of PINK1 protein on damaged mitochondria, which might increase mitochondrial degradation by mitophagy (pink line) and/or modulate the activity of NCXmito, mPTP and/or mCU to control the mitochondrial calcium overload (purple line). This calcium influx also causes c-Fos activation, which probably translocates to the nucleus to promote neuroprotective signaling.

ω -CTX	ω -conotoxin GVIA
PARL	presenilin-associated rhomboid-like
PBS	phosphate buffered saline
PINK1	PTEN-induced kinase 1
PVDF	polyvinylidene fluoride
PI	propidium iodide
PD	Parkinson's disease
TMRM	tetramethylrhodamine methyl ester
TBST	Tris-buffered saline with Tween 20
UPS	ubiquitin-proteasome system
VDAC	voltage-dependent anion channel
VDCC	voltage-dependent calcium channel

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.nbd.2013.10.021>.

Funding

This work was supported by FUNDESALUD [PRIS11014]; Gobierno de Extremadura [GR10054]; Instituto de Salud Carlos III [PI11/00040, PI12/02280, CB06/05/0041]; and Wellcome Trust/MRC Joint Call in Neurodegeneration award [WT089698] to the UK Parkinson's Disease Consortium (UKPDC). R.G-S. was supported by a FPU predoctoral fellowship (Ministerio de Educación, Spain), M.E.G. was supported by the Wellcome Trust/MRC Joint Call in Neurodegeneration award [WT089698] to UKPDC (United Kingdom), J.M.B-S. was supported by a postdoctoral contract (Ligue Nationale Contre le Cancer, France), M.N-S. was supported by a postdoctoral fellowship (Gobierno de Extremadura, Spain), L.A-E. was supported by a Senior Research Fellowship (Parkinson's UK, United Kingdom), E.P-E. was supported by a predoctoral fellowship (CIBERNED, Instituto de Salud Carlos III, Spain).

R.A.G-P. was supported by a "Miguel Servet" research contract (Instituto de Salud Carlos III, Spain).

Conflict of interest statement

None declared.

Acknowledgments

The authors would like to thank R. Ronco and P. Delgado for invaluable technical assistance. Also, F.E. Martín-Cano for the capture of confocal images. We thank Dr. Terje Johansen (Molecular Cancer Research group, Institute of Medical Biology, University of Tromsø, Norway) and Tamotsu Yoshimori (Department of Genetics, Osaka University Graduate School of Medicine, Japan) for kindly providing mCherry-GFP-LC3 and GFP-LC3 constructs, respectively.

References

- Abramov, A.Y., et al., 2011. Bioenergetic consequences of PINK1 mutations in Parkinson disease. *PLoS One* 6, e25622.
- Akundi, R.S., et al., 2011. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. *PLoS One* 6, e16038.
- Ardon, F., et al., 2009. Mitochondrial inhibitors activate influx of external Ca^{2+} in sea urchin sperm. *Biochim. Biophys. Acta* 1787, 15–24.
- Babcock, D.F., et al., 1997. Mitochondrial participation in the intracellular Ca^{2+} network. *J. Cell Biol.* 136, 833–844.
- Beal, M.F., 1998. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. *Ann. Neurol.* 44, S110–S114.
- Beilina, A., et al., 2005. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. *Proc. Natl. Acad. Sci. U. S. A.* 102, 5703–5708.
- Biswas, G., et al., 1999. Retrograde Ca^{2+} signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic stress: a novel mode of inter-organelle crosstalk. *EMBO J.* 18, 522–533.

- Bolte, S., Cordelieres, F.P., 2006. A guided tour into subcellular colocalization analysis in light microscopy. *J. Microsc.* 224, 213–232.
- Bonifati, V., et al., 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 299, 256–259.
- Bravo-San Pedro, J.M., et al., 2013. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. *Cell. Mol. Life Sci.* 70, 121–136.
- Buckler, K.J., Vaughan-Jones, R.D., 1998. Effects of mitochondrial uncouplers on intracellular calcium, pH and membrane potential in rat carotid body type I cells. *J. Physiol.* 513 (Pt 3), 819–833.
- Cali, T., et al., 2013. Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca²⁺ transfer to sustain cell bioenergetics. *Biochim. Biophys. Acta* 1832, 495–508.
- Camandola, S., et al., 2005. Suppression of calcium release from inositol 1,4,5-trisphosphate-sensitive stores mediates the anti-apoptotic function of nuclear factor-kappaB. *J. Biol. Chem.* 280, 22287–22296.
- Chan, N.C., et al., 2011. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum. Mol. Genet.* 20, 1726–1737.
- Cho, S., et al., 2001. Early c-Fos induction after cerebral ischemia: a possible neuroprotective role. *J. Cereb. Blood Flow Metab.* 21, 550–556.
- Clark, J.B., Land, J.M., 1974. Differential effects of 2-oxo acids on pyruvate utilization and fatty acid synthesis in rat brain. *Biochem. J.* 140, 25–29.
- Clark, I.E., et al., 2006. *Drosophila* pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature* 441, 1162–1166.
- Deas, E., et al., 2011. PINK1 cleavage at position A103 by the mitochondrial protease PARL. *Hum. Mol. Genet.* 20, 867–879.
- Devi, L., et al., 2008. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. *J. Biol. Chem.* 283, 9089–9100.
- Duvoisin, R.C., 1999. Genetic and environmental factors in Parkinson's disease. *Adv. Neurol.* 80, 161–163.
- Eilam, Y., et al., 1990. Transient increase in Ca²⁺ influx in *Saccharomyces cerevisiae* in response to glucose: effects of intracellular acidification and cAMP levels. *J. Gen. Microbiol.* 136, 2537–2543.
- Fuentes, J.M., et al., 2000. Clean Western blots of membrane proteins after yeast heterologous expression following a shortened version of the method of Perini et al. *Anal. Biochem.* 285, 276–278.
- Furukawa, K., Mattson, M.P., 1998. The transcription factor NF-kappaB mediates increases in calcium currents and decreases in NMDA- and AMPA/kainate-induced currents induced by tumor necrosis factor-alpha in hippocampal neurons. *J. Neurochem.* 70, 1876–1886.
- Gandhi, S., et al., 2009. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. *Mol. Cell* 33, 627–638.
- Gautier, C.A., et al., 2008. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. *Proc. Natl. Acad. Sci. U. S. A.* 105, 11364–11369.
- Gautier, C.A., et al., 2012. Regulation of mitochondrial permeability transition pore by PINK1. *Mol. Neurodegener.* 7, 22.
- Gegg, M.E., et al., 2009. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. *PLoS One* 4, e4756.
- Gegg, M.E., et al., 2010. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. *Hum. Mol. Genet.* 19, 4861–4870.
- Geisler, S., et al., 2010. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat. Cell Biol.* 12, 119–131.
- Gispert, S., et al., 2009. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. *PLoS One* 4, e5777.
- Goldberg, J.A., et al., 2012. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. *Nat. Neurosci.* 15, 1414–1421.
- Gonzalez-Polo, R.A., et al., 2007. Inhibition of paraquat-induced autophagy accelerates the apoptotic cell death in neuroblastoma SH-SY5Y cells. *Toxicol. Sci.* 97, 448–458.
- Greene, A.W., et al., 2012. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. *EMBO Rep.* 13, 378–385.
- Grunewald, A., et al., 2009. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. *Exp. Neurol.* 219, 266–273.
- Guzman, J.N., et al., 2010. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. *Nature* 468, 696–700.
- Haque, M.E., et al., 2008. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. *Proc. Natl. Acad. Sci. U. S. A.* 105, 1716–1721.
- Heeman, B., et al., 2011. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. *J. Cell Sci.* 124, 1115–1125.
- Herrington, J., et al., 1996. Dominant role of mitochondria in clearance of large Ca²⁺ loads from rat adrenal chromaffin cells. *Neuron* 16, 219–228.
- Hoepken, H.H., et al., 2007. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. *Neurobiol. Dis.* 25, 401–411.
- Ilijic, E., et al., 2011. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. *Neurobiol. Dis.* 43, 364–371.
- Jin, S.M., et al., 2010. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J. Cell Biol.* 191, 933–942.
- Kabeya, Y., et al., 2000. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosomal membranes after processing. *EMBO J.* 19, 5720–5728.
- Kim, I., et al., 2007. Selective degradation of mitochondria by mitophagy. *Arch. Biochem. Biophys.* 462, 245–253.
- Komori, Y., et al., 2010. Ca²⁺ homeostasis, Ca²⁺ signalling and somatodendritic vasopressin release in adult rat supraoptic nucleus neurones. *Cell Calcium* 48, 324–332.
- Kondapalli, C., et al., 2012. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. *Open Biol.* 2, 120080.
- Langston, J.W., et al., 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219, 979–980.
- Li, B., et al., 1999. Respiratory uncoupling induces delta-aminolevulinic synthase expression through a nuclear respiratory factor-1-dependent mechanism in HeLa cells. *J. Biol. Chem.* 274, 17534–17540.
- Lim, D.Y., et al., 2006. CCCP enhances catecholamine release from the perfused rat adrenal medulla. *Auton. Neurosci.* 128, 37–47.
- Lin, W., Kang, U.J., 2008. Characterization of PINK1 processing, stability, and subcellular localization. *J. Neurochem.* 106, 464–474.
- Lyons, M.R., West, A.E., 2011. Mechanisms of specificity in neuronal activity-regulated gene transcription. *Prog. Neurobiol.* 94, 259–295.
- Marongiu, R., et al., 2009. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. *J. Neurochem.* 108, 1561–1574.
- Matsuda, N., et al., 2010. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J. Cell Biol.* 189, 211–221.
- Mei, Y., et al., 2009. FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. *Proc. Natl. Acad. Sci. U. S. A.* 106, 5153–5158.
- Meissner, C., et al., 2011. The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. *J. Neurochem.* 117, 856–867.
- Mo, R.H., et al., 2012. Effects of Lipofectamine 2000/siRNA complexes on autophagy in hepatoma cells. *Mol. Biotechnol.* 51, 1–8.
- Mouatt-Prigent, A., et al., 1994. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? *Brain Res.* 668, 62–70.
- Muqit, M.M., et al., 2006. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. *J. Neurochem.* 98, 156–169.
- Narendra, D., et al., 2008. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J. Cell Biol.* 183, 795–803.
- Narendra, D., et al., 2010a. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. *Autophagy* 6, 1090–1106.
- Narendra, D.P., et al., 2010b. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol.* 8, e1000298.
- Neher, E., Sakaba, T., 2008. Multiple roles of calcium ions in the regulation of neurotransmitter release. *Neuron* 59, 861–872.
- Ng, S.W., et al., 2012. Cysteinyln leukotriene type I receptor desensitization sustains Ca²⁺-dependent gene expression. *Nature* 482, 111–115.
- Pankiv, S., et al., 2007. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J. Biol. Chem.* 282, 24131–24145.
- Papkovskia, T.D., et al., 2012. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. *Hum. Mol. Genet.* 21, 4201–4213.
- Park, J., et al., 2006. Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin. *Nature* 441, 1157–1161.
- Pereira, M.B., et al., 2008. Carbonyl cyanide m-chlorophenylhydrazone induced calcium signaling and activation of plasma membrane H⁺-ATPase in the yeast *Saccharomyces cerevisiae*. *FEMS Yeast Res.* 8, 622–630.
- Petit, A., et al., 2005. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. *J. Biol. Chem.* 280, 34025–34032.
- Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 29, e45.
- Piccoli, C., et al., 2008. Mitochondrial respiratory dysfunction in familial parkinsonism associated with PINK1 mutation. *Neurochem. Res.* 33, 2565–2574.
- Poole, A.C., et al., 2008. The PINK1/Parkin pathway regulates mitochondrial morphology. *Proc. Natl. Acad. Sci. U. S. A.* 105, 1638–1643.
- Premkumar, D.R., et al., 2000. L-type Ca²⁺ channel activation regulates induction of c-fos transcription by hypoxia. *J. Appl. Physiol.* 88, 1998–2006.
- Sandebing, A., et al., 2009. Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. *PLoS One* 4, e5701.
- Sato, M., 1997. Effects of the removal of extracellular Ca²⁺ on [Ca²⁺]_i responses to FCCP and acetate in carotid body glomus cells of adult rabbits. *Brain Res.* 768, 37–42.
- Schapiro, A.H., et al., 1989. Mitochondrial complex I deficiency in Parkinson's disease. *Lancet* 1, 1269.
- Sengupta, A., et al., 2011. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. *J. Biol. Chem.* 286, 7468–7478.
- Shiba-Fukushima, K., et al., 2012. PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. *Sci. Rep.* 2, 1002.
- Silvestri, L., et al., 2005. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. *Hum. Mol. Genet.* 14, 3477–3492.
- Sim, C.H., et al., 2006. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. *Hum. Mol. Genet.* 15, 3251–3262.
- Soriano, F.X., et al., 2006. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. *J. Neurosci.* 26, 4509–4518.
- Takatori, S., et al., 2008. Cytoplasmic localization and proteasomal degradation of N-terminally cleaved form of PINK1. *Neurosci. Lett.* 430, 13–17.
- Tanaka, A., et al., 2010. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. *J. Cell Biol.* 191, 1367–1380.
- Thompson, M.A., et al., 1995. L-type voltage-sensitive Ca²⁺ channel activation regulates c-fos transcription at multiple levels. *J. Biol. Chem.* 270, 4224–4235.

- Tonkikh, A.A., Carlen, P.L., 2009. Impaired presynaptic cytosolic and mitochondrial calcium dynamics in aged compared to young adult hippocampal CA1 synapses ameliorated by calcium chelation. *Neuroscience* 159, 1300–1308.
- Twig, G., et al., 2008. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. *EMBO J.* 27, 433–446.
- Valente, E.M., et al., 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* 304, 1158–1160.
- Vives-Bauza, C., et al., 2010. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proc. Natl. Acad. Sci. U. S. A.* 107, 378–383.
- Weihofen, A., et al., 2008. Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. *Hum. Mol. Genet.* 17, 602–616.
- Whitworth, A.J., et al., 2008. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. *Dis. Model Mech.* 1, 168–174 (discussion 173).
- Williams, A.C., et al., 1999. Idiopathic Parkinson's disease: a genetic and environmental model. *Adv. Neurol.* 80, 215–218.
- Wood-Kaczmar, A., et al., 2008. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. *PLoS One* 3, e2455.
- Wood-Kaczmar, A., et al., 2013. The role of the mitochondrial NCX in the mechanism of neurodegeneration in Parkinson's disease. *Adv. Exp. Med. Biol.* 961, 241–249.
- Yamada, T., et al., 1990. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. *Brain Res.* 526, 303–307.
- Yan, L., et al., 2012. Ca²⁺ homeostasis and exocytosis in carotid glomus cells: role of mitochondria. *Cell Calcium* 51, 155–163.
- Yang, Y., et al., 2008. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. *Proc. Natl. Acad. Sci. U. S. A.* 105, 7070–7075.
- Youle, R.J., Narendra, D.P., 2011. Mechanisms of mitophagy. *Nat. Rev. Mol. Cell Biol.* 12, 9–14.
- Zhang, J., et al., 2002. c-fos regulates neuronal excitability and survival. *Nat. Genet.* 30, 416–420.
- Zhang, J., et al., 2009. Isoflurane inhibits cyclic adenosine monophosphate response element-binding protein phosphorylation and calmodulin translocation to the nucleus of SH-SY5Y cells. *Anesth. Analg.* 109, 1127–1134.
- Zhao, R., et al., 2007. Ca²⁺ influx through both L- and N-type Ca²⁺ channels increases c-fos expression by electrical stimulation of sympathetic neurons. *Eur. J. Neurosci.* 25, 1127–1135.
- Zhou, C., et al., 2008. The kinase domain of mitochondrial PINK1 faces the cytoplasm. *Proc. Natl. Acad. Sci. U. S. A.* 105, 12022–12027.
- Ziviani, E., et al., 2010. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. *Proc. Natl. Acad. Sci. U. S. A.* 107, 5018–5023.
- Zucker, R.S., 1999. Calcium- and activity-dependent synaptic plasticity. *Curr. Opin. Neurobiol.* 9, 305–313.